Zealand Pharma finishes phase III enrollment

All patients have been found for a phase III study of a potential hyperinsulinism treatment for children, reports Zealand Pharma.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

Zealand Pharma has announced that recruitment for an upcoming phase III study with a drug candidate, dasiglucagon, designed to treat infants up to 12 months of age with congenital hyperinsulinism (CHI), has been completed, a company press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading